BLTE
Belite Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Consensus Rating "Buy"
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BLTE
Belite Bio, Inc
A biopharmaceutical company developing new treatments for currently incurable eye diseases
Pharmaceutical
03/27/2018
04/29/2022
NASDAQ Stock Exchange
25
12-31
Depository Receipts (Ordinary Shares)
12750 High Bluff Drive Suite 475, San Diego, CA 92130
--
Belite Bio, Inc was incorporated in the Cayman Islands on March 27, 2018. The Company is a clinical-stage biopharmaceutical and drug development company focused on novel therapies for currently untreatable eye diseases involving retinal degeneration with significant unmet medical needs, such as (i) atrophic age-related macular degeneration (AMD), commonly known as geographic atrophy (GA), or advanced dry AMD, and (ii) autorecessive chromosomal Stargardt disease type 1, or STGD1, Both diseases can lead to progressive vision loss, leading to permanent blindness. The company's drug pipeline also includes a small molecule oral compound for the treatment of metabolic diseases such as non-alcoholic fatty liver, non-alcoholic steatohepatitis, NASH, type 2 diabetes, T2D and gout.
Earnings Call
Q2/2025
Estimate EPS-0.42
Actual EPS-0.31
Estimate Revenue--
Actual Revenue0
Belite Bio's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Financial Outlook
Aug 11,2025 11:45
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.49
Actual EPS-0.65
Estimate Revenue--
Actual Revenue0
Belite Bio's Q3 2025 Earnings Call: Contradictions in Regulatory Timelines, Commercialization Plans, SG&A Forecasts, and PHOENIX Trial Strategy
Nov 10,2025 06:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BLTE has released its 2025 Q3 earnings. EPS was reported at -0.65, versus the expected -0.49, missing expectations. The chart below visualizes how BLTE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
